PMID- 29762840
OWN - NLM
STAT- MEDLINE
DCOM- 20191022
LR  - 20191022
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 22
IP  - 8
DP  - 2018 Apr
TI  - The effect of miR-146a gene silencing on drug-resistance and expression of 
      protein of P-gp and MRP1 in epilepsy.
PG  - 2372-2379
LID - 14829 [pii]
LID - 10.26355/eurrev_201804_14829 [doi]
AB  - OBJECTIVE: To investigate the effect of miR-146a gene silencing on brain tissue 
      and related drug-resistance proteins in rats and explore its resistance 
      mechanism. MATERIALS AND METHODS: A rat model of chronic refractory epilepsy was 
      established. The rats were divided into four groups: Normal group, Model group, 
      Negative control group and AntagomiR-146a group. Hematoxylin and eosin (HE) stain 
      was used to detect brain histopathological changes. We examined the expression of 
      mRNA of miR-146a, multidrug resistance (MDR1) and multidrug-resistant associated 
      protein (MRP1) by RT-PCR. The expressions of protein of High motility group box 1 
      (HMGB1)/Toll-like receptor 4 (TLR4)/nuclear transcription factor-kappaB (NF-kappaB) 
      pathway and P-glycoprotein (P-gp), MRP1 were detected by Western-blotting. 
      RESULTS: We demonstrated that the pathological lesion was lighter in 
      antagomiR-146a group compared with the model group. The mRNA expression of 
      miR-146a in AntagomiR-146a group was significantly decreased compared to the 
      model group. Furthermore, the mRNA expression of MDR1 and MRP1 in AntagomiR-146a 
      group was lower than that in the model group. In addition, the protein expression 
      of HMGB1, TLR4, NF-kappaB and P-gp, MRP1 in AntagomiR-146a group was lower than that 
      in model group. CONCLUSIONS: These results demonstrated that miR-146a gene 
      silencing can attenuate pathological changes and improve drug resistance in 
      refractory epilepsy. Also, it is closely related to the HMGB1/TLR4/NF-kappaB 
      signaling pathway regulation.
FAU - Zhang, H-L
AU  - Zhang HL
AD  - Department of Neurology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, Shandong, China. qichen201612@126.com.
FAU - Lin, Y-H
AU  - Lin YH
FAU - Qu, Y
AU  - Qu Y
FAU - Chen, Q
AU  - Chen Q
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 1)
RN  - 0 (Antagomirs)
RN  - 0 (HMGB1 Protein)
RN  - 0 (MIRN146a microRNA, rat)
RN  - 0 (MicroRNAs)
RN  - 0 (Multidrug Resistance-Associated Proteins)
RN  - 0 (NF-kappa B)
RN  - 0 (Toll-Like Receptor 4)
RN  - Y49M64GZ4Q (multidrug resistance-associated protein 1)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 1/*metabolism
MH  - Animals
MH  - Antagomirs/metabolism
MH  - Disease Models, Animal
MH  - Epilepsy/metabolism/*pathology
MH  - Gene Silencing
MH  - HMGB1 Protein/metabolism
MH  - MicroRNAs/antagonists & inhibitors/genetics/*metabolism
MH  - Multidrug Resistance-Associated Proteins/*metabolism
MH  - NF-kappa B/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Signal Transduction
MH  - Toll-Like Receptor 4/metabolism
EDAT- 2018/05/16 06:00
MHDA- 2019/10/23 06:00
CRDT- 2018/05/16 06:00
PHST- 2018/05/16 06:00 [entrez]
PHST- 2018/05/16 06:00 [pubmed]
PHST- 2019/10/23 06:00 [medline]
AID - 14829 [pii]
AID - 10.26355/eurrev_201804_14829 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2018 Apr;22(8):2372-2379. doi: 
      10.26355/eurrev_201804_14829.